Diagnosis and Management of Drug-Induced Interstitial Lung Disease Associated with Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium Avium Complex Pulmonary Disea... by Hashimoto K, Nii T, Sumitani H, Yokoyama M, Miyamoto S, Mihashi Y, Nagata Y, Matsuki T, Tsujino K, Miki K, Kida H

Get full text

Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. by Chen, J, Dunbar, P, Gileadi, U, Jäger, E, Gnjatic, S, Nagata, Y, Stockert, E, Panicali, D, Chen, Y, Knuth, A, Old, L, Cerundolo, V

Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. by Gnjatic, S, Nagata, Y, Jager, E, Stockert, E, Shankara, S, Roberts, B, Mazzara, G, Lee, S, Dunbar, P, Dupont, B, Cerundolo, V, Ritter, G, Chen, Y, Knuth, A, Old, L

Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. by Jäger, E, Nagata, Y, Gnjatic, S, Wada, H, Stockert, E, Karbach, J, Dunbar, P, Lee, S, Jungbluth, A, Jäger, D, Arand, M, Ritter, G, Cerundolo, V, Dupont, B, Chen, Y, Old, L, Knuth, A

Recent Developments from ASACUSA on Antihydrogen Detection by Kolbinger B., Amsler C., Breuker H., Diermaier M., Dupré P., Fleck M., Gligorova A., Higaki H., Kanai Y., Kobayashi T., Leali M., Mäckel V., Malbrunot C., Mascagna V., Massiczek O., Matsuda Y., Murtagh D.j., Nagata Y., Sauerzopf C., Simon M.C., Tajima M., Ulmer S., Kuroda N., Venturelli L., Widmann E., Yamazaki Y., Zmeskal J.

Get full text

Minimizing plasma temperature for antimatter mixing experiments by Hunter E.D., Amsler C., Breuker H., Chesnevskaya S., Costantini G., Ferragut R., Giammarchi M., Gligorova A., Gosta G., Higaki H., Kanai Y., Killian C., Kletzl V., Kraxberger V., Kuroda N., Lanz A., Leali M., Mäckel V., Maero G., Malbrunot C., Mascagna V., Matsuda Y., Migliorati S., Murtagh D.J., Nagata Y., Nanda A., Nowak L., Pasino E., Romé M., Simon M.C., Tajima M., Toso V., Ulmer S., Uggerhøj U., Venturelli L., Weiser A., Widmann E., Wolz T., Yamazaki Y., Zmeskal J.

Get full text

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups by Haase, D, Stevenson, KE, Neuberg, D, Maciejewski, JP, Nazha, A, Sekeres, MA, Ebert, BL, Garcia-Manero, G, Haferlach, C, Haferlach, T, Kern, W, Ogawa, S, Nagata, Y, Yoshida, K, Graubert, TA, Walter, MJ, List, AF, Komrokji, RS, Padron, E, Sallman, D, Papaemmanuil, E, Campbell, PJ, Savona, MR, Seegmiller, A, Adès, L, Fenaux, P, Shih, L-Y, Bowen, D, Groves, MJ, Tauro, S, Fontenay, M, Kosmider, O, Bar-Natan, M, Steensma, D, Stone, R, Heuser, M, Thol, F, Cazzola, M, Malcovati, L, Karsan, A, Ganster, C, Hellström-Lindberg, E, Boultwood, J, Pellagatti, A, Santini, V, Quek, L, Vyas, P, Tüchler, H, Greenberg, PL, Bejar, R, International Working Group For Mds Molecular Prognostic Committee